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ABSTRACT The repetitive interspersed family (RIFIN) and the subtelomeric variable
open reading frame (STEVOR) family represent two of three major Plasmodium falci-
parum variant surface antigen families involved in malaria pathogenesis and immune
evasion and are potential targets in the development of natural immunity. Pro-
tein and peptide microarrays populated with RIFINs and STEVORs associated with
severe malaria vulnerability in Malian children were probed with adult and pedi-
atric sera to identify epitopes that reﬂect malaria exposure. Adult sera recog-
nized and reacted with greater intensity to all STEVOR proteins than pediatric
sera did. Serorecognition of and seroreactivity to peptides within the semicon-
served domain of STEVORs increased with age and seasonal malaria exposure,
while serorecognition and seroreactivity increased for the semiconserved and
second hypervariable domains of RIFINs only with age. Serologic responses to
RIFIN and STEVOR peptides within the semiconserved domains may play a role in
natural immunity to severe malaria.
IMPORTANCE Malaria, an infectious disease caused by the parasite Plasmodium fal-
ciparum, causes nearly 435,000 deaths annually worldwide. RIFINs and STEVORs are
two variant surface antigen families that are involved in malaria pathogenesis and
immune evasion. Recent work has shown that a lack of humoral immunity to these
proteins is associated with severe malaria vulnerability in Malian children. This is the
ﬁrst study to have compared serologic responses of children and adults to RIFINs
and STEVORs in settings of malaria endemicity and to examine such serologic re-
sponses before and after a clinical malaria episode. Using microarrays, we deter-
mined that the semiconserved domains in these two parasite variant surface antigen
families harbor peptides whose seroreactivity reﬂects malaria exposure. A similar ap-
proach has the potential to illuminate the role of variant surface antigens in the de-
velopment of natural immunity to clinical malaria. Potential vaccines for severe ma-
laria should include consideration of peptides within the semiconserved domains of
RIFINs and STEVORs.
KEYWORDS Plasmodium falciparum, RIFIN, STEVOR, malaria, microarrays, peptide,
semiconserved domain, severe malaria, variant surface antigen
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Malaria in humans is primarily caused by Plasmodium falciparum, accounting for435,000 annual deaths worldwide in 2017 (1). Repetitive interspersed family
(RIFIN) and subtelomeric variable open reading frame (STEVOR) proteins are two P.
falciparum variant surface antigen (VSA) families involved in malaria pathogenesis and
immune evasion (2–8). Individuals in regions where malaria is endemic likely acquire
natural immunity to clinical disease due to production of antibodies against certain
VSAs (8–12), but little is known about the relative contributions of antibodies against
RIFINs and STEVORs for protection against malaria disease (reviewed in references
13–15).
P. falciparum reference genome 3D7 includes 160 rif genes and 30 stevor genes
encoding RIFIN and STEVOR proteins, respectively. Both gene families exhibit high
sequence diversity (16–18). These proteins are exported to the infected red blood cell
surface where portions become exposed to the immune system. RIFINs and STEVORs
feature a domain architecture consisting of a signal sequence, a short variable domain
(V1), a PEXEL motif, a semiconserved (SC) domain, a second hypervariable domain (V2),
and a transmembrane domain inserted into the erythrocyte membrane that precedes
a conserved C terminus (Fig. 1). RIFINs are divided into two subfamilies, RIFIN-A and
RIFIN-B, with the latter group localized subcellularly (6). RIFIN-As have a unique
25-amino-acid insertion sequence within the SC domain and, typically, a single trans-
membrane domain (16, 18–20). A number of STEVORs have a second transmembrane
domain, similar to RIFIN-Bs (13).
Particular RIFINs may serve as important targets in the development of natural
immunity to severe malaria (3, 8, 21, 22). Increased antibody titers corresponding to
four recombinant RIFINs correlated with suppression of malaria symptoms and rapid
parasite clearance in asymptomatic Gabonese children (23). Anti-RIFIN antibodies may
limit disease severity by disrupting rosette formation (24), promoting phagocytosis of
infected red blood cells (21), and preventing RIFIN binding to host leukocyte
immunoglobulin-like receptor B1 (LILRB1) (3). Such RIFIN binding to LILRB1 receptors
on B and NK immune cells limits the host immune response, potentially increasing
susceptibility to severe malaria.
We are only beginning to understand natural immunity to STEVOR proteins. Anti-
bodies to STEVORs weakly inhibit merozoite adhesion and invasion in vitro (25, 26).
Given the structural similarity of STEVORs and RIFINs (18), it is possible that antibodies
to STEVORs may play a role in clinical protection.
We recently identiﬁed a subset of RIFINs and STEVORs associated with severe
malaria vulnerability in Malian children (22). Sera from children with severe malaria
exhibited gaps in immunity, designated “lacunae,” to three RIFINs and three STEVORs
compared with matched sera from children with uncomplicated malaria infections.
Given these ﬁndings, we further examined the serologic response to this subset of
RIFINs and STEVORs in Malian children and adults. Our goal was to identify the RIFIN
and STEVOR domains and amino acid residues that contain epitopes reﬂecting malaria
exposure. We hypothesized that antibodies against RIFINs and STEVORs would target
more epitopes within the SC domain than within the V1 and V2 domains, given the SC
domain’s membrane orientation and relative sequence homology (18, 27, 28).
FIG 1 General structure of RIFINs and STEVORs. Protein domains are illustrated as green (signal peptide [SP]), gray
(short hypervariable domain [V1] and hypervariable domain [V2]), red (transmembrane domains [TM]), black (PEXEL
motif), blue (25-amino-acid sequence found only in RIFIN-A antigens), or orange/purple (semiconserved [SC] or
conserved [C] domain). RIFINs are encoded by 160 rif genes in the 3D7 reference genome, separated into two
subtypes, RIFIN-A and RIFIN-B, depending on sequence, number of transmembrane domains, and subcellular
localization. Thirty 3D7 genes encode STEVORs, which are structurally similar to RIFIN-Bs.
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Protein and peptide microarrays are tools that permit analyses of immune responses
to large numbers of malaria proteins and constituent amino acid residues (29, 30).
Protein microarrays measure levels of antibody binding to tertiary protein structures,
while peptide arrays provide increased resolution to detect individual epitopes. We
populated protein and peptide microarrays with these three RIFINs and three STEVORs
associated with severe malaria vulnerability as well as with three additional STEVORs
and probed them with sera from Malian adults and children to identify epitopes that
are serorecognized and seroreactive after naturally acquired malaria infection.
(This work was presented in part at the 66th annual meeting of the American Society
of Tropical Medicine and Hygiene, Baltimore, MD [31], and at the 67th annual meeting
of the American Society of Tropical Medicine and Hygiene in New Orleans, LA, October
2018 [32].)
RESULTS
Malian adults had greater seroreactivity to STEVOR proteins than Malian
children. Sera from Malian adults recognized all three RIFINs and six STEVORs on the
protein microarray, while sera from Malian children recognized all three RIFINs but only
four of the six STEVORs (P. falciparum 3D7_1300900 [PF3D7_1300900], PF3D7_0300400,
PF3D7_0115400, and PF3D7_1254100) (Table 1), including two associated with cerebral
malaria vulnerability (PF3D7_0300400 and PF3D7_0115400) (22). The two STEVORs that
were not recognized by pediatric sera were PF3D7_0832000 and PF3D7_0832600. The
former is associated with vulnerability to cerebral malaria as well as severe malarial
anemia (22).
Sera from Malian adults reacted more intensely to all six STEVORs than the pediatric
sera did. In contrast, the levels of RIFIN seroreactivity were comparable between the
two groups, with no signiﬁcant differences (Fig. 2).
“Serorecognition” of and seroreactivity to peptides within the semiconserved
domains and second hypervariable (V2) domains of all three RIFINs reﬂect age-
related differences in malaria exposure. For each of the three RIFINs, Malian adult
sera recognized signiﬁcantly more total peptides than the pediatric sera did (Fig. 3A).
For all three RIFINs, Malian adults had greater counts of serorecognized peptides in the
SC and V2 domains than Malian children did, whereas in the V1 domain, this was true
for two of the three RIFINs (Table 2). In contrast to the protein microarray results, the
peptide array data showed differential levels of RIFIN seroreactivity between Malian
adults and children. Adult sera had greater seroreactivity to several subsets of RIFIN
peptides in the V1, SC, and V2 domains than the pediatric sera did (Fig. 3C).
Sera collected at day 90 during the transmission season from children who had
already experienced at least one clinical malaria episode showed serorecognition of
signiﬁcantly more total peptides for each of the three RIFIN proteins than paired
TABLE 1 Sera from Malian adults recognized a greater number of STEVORs than pediatric
sera
Surface antigen
Serorecognitiona
Adults (n 18) Children (n 75)
RIFINs
PF3D7_0732400 ✓ ✓
PF3D7_1041100 ✓ ✓
PF3D7_0732400 ✓ ✓
STEVORs
PF3D7_1300900 ✓ ✓
PF3D7_0832000 ✓ X
PF3D7_0832600 ✓ X
PF3D7_0300400 ✓ ✓
PF3D7_0115400 ✓ ✓
PF3D7_1254100 ✓ ✓
a✓, serorecognition; X, lack of serorecognition.
RIFIN and STEVOR Peptides Reﬂect Malaria Exposure
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preseason pediatric sera (Fig. 4A). These seasonal differences were not consistently
signiﬁcant for the V1, SC, or V2 RIFIN domains alone (Table 2). Day 90 pediatric sera did
not consistently react more intensely than day 0 preseason sera to any group of
peptides within a particular RIFIN domain (Fig. 4C). Similar patterns were present in sera
from all children (see Fig. S1 in the supplemental material). In contrast, samples
collected from children who did not experience a malaria episode during the malaria
transmission season did not differ from preseason sera in counts of recognized pep-
tides for any of the three RIFIN proteins (n 4; Fig. S2).
Serorecognition of and seroreactivity to peptides within the semiconserved
domains of STEVORs reﬂect differences in age and seasonal malaria exposure. For
each of the six STEVORs, Malian adult sera recognized signiﬁcantly more total peptides
than pediatric sera. These age-related differences were also present for particular
individual STEVOR domains. For each of the six STEVORs, adult sera recognized more
peptides in the SC and V2 domains than the pediatric sera (Fig. 3B; see also Table 2).
In contrast, children did not differ from adults in counts of recognized V1 domain
peptides for four of the six STEVORs. Adult sera also reacted more intensely to subsets
of STEVOR peptides within the SC and V2 domains than pediatric sera (Fig. 3C and D).
Pediatric sera collected during the malaria transmission season from children who
had already experienced at least one clinical malaria episode recognized signiﬁcantly
more peptides across the full length of each of the six STEVORs than pediatric sera from
the same children collected before the start of the transmission season (Fig. 4B). These
seasonal differences were signiﬁcant for individual STEVOR domains: day 90 sera
recognized more peptides within the SC domain than preseason sera for each of the six
STEVORs, but this was not the case for any of the V1 domains (Table 2). Day 90 pediatric
sera reacted more intensely than day 0 sera to subsets of STEVOR peptides within the
SC domains of four STEVORs (PF3D7_1300900, PF3D7_0300400, PF3D7_0115400, and
PF3D7_1254100) (Fig. 4D). Similar seasonal trends were present in sera from all children
(Fig. S1). In contrast, sera collected from children who did not experience a malaria
episode during the malaria transmission season did not differ from preseason sera in
counts of recognized peptides for any of the six STEVOR proteins (n 4; Fig. S2).
Semiconserved and second hypervariable (V2) VSA domains harbor peptides
reﬂecting malaria exposure. We identiﬁed peptides that were both serorecognized
FIG 2 Protein microarray seroreactivity of three RIFINs (black) and six STEVORs (purple). Malian adult sera exhibited greater seroreactivity to all six STEVORs
than pediatric sera. There were no signiﬁcant differences between adult and pediatric seroreactivity to the three RIFINs. Data representing ﬂuorescence intensity
(FI) for sera from adults (n 18) and children (n 75) were compared using a Mann-Whitney test (**, P 0.01; *** P 0.001). The y axis shows seroreactivity
represented by mean ﬂuorescence intensity. Each box plot shows the median, bracketed by the lower 25th and upper 75th percentiles, and the minimum and
maximum values.
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and differentially seroreactive in group comparisons. These peptides were present
throughout all three RIFIN and six STEVOR proteins (Fig. 5; see also Table S1 in the
supplemental material). Such peptides differentiating sera of children from sera of
adults were consistently located in the RIFIN V2 domain and in both the SC and V2
FIG 3 Malaria-exposed adults (n 10) demonstrated greater serorecognition of and seroreactivity to peptides of three RIFINs (A and C) and six STEVORs (B
and D) than children (n 10) as measured using peptide microarrays. (A and B) Malian adult sera (red) recognized signiﬁcantly more (A) RIFIN and (B) STEVOR
total peptides than preseason pediatric sera (blue). The horizontal axis depicts the relative location of the N-terminal amino acid for each peptide. ***, signiﬁcant
difference between adults and children in serorecognized peptide counts (P 0.05; McNemar’s test). (C and D) Malian adult sera (red) had increased
seroreactivity to subsets of (C) RIFIN and (D) STEVOR peptides compared with pediatric sera (blue) (P values are indicated in gray on the secondary y axis;
Wilcoxon rank-sum test).
RIFIN and STEVOR Peptides Reﬂect Malaria Exposure
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STEVOR domains (Fig. 5A and B). Similarly, these peptides differentiating sera collected
before the malaria transmission season from sera collected during the malaria trans-
mission season for children experiencing clinical malaria episodes were sparse and not
uniformly located within any of the three RIFINs, whereas the semiconserved domain
consistently harbored such STEVOR peptides (Fig. 5C and D).
DISCUSSION
We previously identiﬁed three RIFINs and three STEVORs associated with severe
malaria vulnerability in Malian children (22). Here, we determined that the semicon-
served domains of these RIFINs and STEVORs were hot spots for peptides associated
with malaria exposure. These peptides likely include epitopes and may contain critical
amino acid residues associated with malaria exposure and, potentially, with immunity
to clinical malaria.
Protein microarray data demonstrated age-related differences in serologic re-
sponses to RIFINs and STEVORs. Serorecognition of the three RIFINs and six STEVORs
differentiated between Malian adults and malaria-naive North American controls but
not consistently between Malian children and North American controls. Children had
signatures of serorecognition to all three RIFINs but to only four of the six STEVORs,
indicating that serorecognition of RIFINs may be acquired early in life, while serorecog-
nition of STEVORs may be acquired more gradually. Protein seroreactivity comparisons
reﬂected similar age-related differences. Malian adult sera reacted more intensely than
pediatric sera to all six STEVORs but not differentially to any of the three RIFINs.
Peptide microarray data revealed age-related differences in seroreactivity and al-
lowed localization of the discriminatory antibody responses to particular regions within
each protein. Adult sera recognized signiﬁcantly more peptides in the semiconserved
and V2 domains of all three RIFINs and six STEVORs than pediatric sera. Likewise, adult
sera had more reactivity than pediatric sera to subsets of peptides across each of the
nine antigens. Only serorecognition of peptides within the STEVOR semiconserved
domain and increased reactivity to peptides within the semiconserved domains of four
STEVORs consistently differentiated between pediatric sera obtained at the beginning
TABLE 2 Summary of peptide serorecognition comparisons for the domains of three RIFINs and six STEVORs
Surface antigen and serum group
No. of peptides recognized (P value)a
Total V1 SC V2
RIFIN
Adults vs Pediatric
PF3D7_0833200 143 vs 12*** 19 vs 0** 35 vs 9*** 73 vs 3***
PF3D7_1041100 114 vs 31*** 3 vs 0 (0.617) 32 vs 17*** 55 vs 13***
PF3D7_0732400 187 vs 39*** 15 vs 4** 26 vs 16** 120 vs 19***
Pediatric Infected—day 90 vs day 0
PF3D7_0833200 99 vs 27*** 15 vs 3 (0.480) 39 vs 13 (0.134) 28 vs 9***
PF3D7_1041100 88 vs 50** 5 vs 5 (1) 37 vs 23 (0.480) 34 vs 18 (0.077)
PF3D7_0732400 139 vs 67*** 12 vs 8 (0.131) 30 vs 16*** 77 vs 34**
STEVORs
Adults vs Pediatric
PF3D7_1254100 135 vs 40*** 13 vs 1** 80 vs 26*** 17 vs 0***
PF3D7_0832000 112 vs 1*** 7 vs 0* 54 vs 1*** 27 vs 0***
PF3D7_0300400 135 vs 38*** 5 vs 0 (0.134) 85 vs 34*** 22 vs 1***
PF3D7_0115400 132 vs 38*** 4 vs 0 (0.371) 81 vs 31*** 24 vs 4***
PF3D7_1300900 133 vs 32*** 3 vs 0 (0.617) 80 vs 26*** 22 vs 3***
PF3D7_0832600 140 vs 10*** 9 vs 1* 80 vs 8*** 29 vs 1***
Pediatric infected—day 90 vs day 0
PF3D7_1254100 106 vs 62*** 13 vs 4 (0.248) 71 vs 49** 8 vs 2 (1)
PF3D7_0832000 64 vs 13*** 1 vs 0 (1) 32 vs 9*** 16 vs 4 (0.617)
PF3D7_0300400 105 vs 62*** 8 vs 1 (0.617) 67 vs 54** 15 vs 3 (0.134)
PF3D7_0115400 107 vs 59*** 3 vs 0 (1) 77 vs 28** 13 vs 9 (1)
PF3D7_1300900 115 vs 58*** 7 vs 0 (1) 79 vs 45*** 13 vs 6*
PF3D7_0832600 82 vs 23*** 9 vs 1 (0.134) 56 vs 18 *** 5 vs 2 (0.480)
a*, P 0.01; **, P 0.001; ***, P 0.0001.
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of the malaria transmission season and the sera obtained during the malaria transmis-
sion season. There was increased serorecognition of and seroreactivity to semicon-
served domain STEVOR peptides during pediatric malaria infections, while seroreactiv-
ity to RIFIN peptides within particular domains was more variable.
FIG 4 Children with recent clinical malaria episodes (n 6) exhibited increased serological responses to three RIFINs (A and C) and six STEVORs (B and
D) during the transmission season as measured using peptide microarrays. (A and B) Day 90 pediatric sera (maroon) recognized signiﬁcantly more (A) RIFIN
and (B) STEVOR peptides in total than the same day 0 pediatric sera from before the malaria season (blue). The x axis depicts the peptide number
corresponding to the sequence from the N terminus to the C terminus for each respective antigen. ***, signiﬁcant difference in serorecognized peptide
counts between day 0 and day 90 (P 0.05; McNemar’s test). (C and D) Day 90 sera (maroon) had increased seroreactivity to subsets of (C) RIFIN and (D)
STEVOR peptides compared with matched sera before the malaria transmission season (blue) (P values in gray; Wilcoxon signed-rank test).
RIFIN and STEVOR Peptides Reﬂect Malaria Exposure
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Our results suggest that the semiconserved domain of RIFINs and STEVORs is
exposed on the erythrocyte surface, given the predominance of peptides that were
both serorecognized and differentially seroreactive in group comparisons within this
region (Fig. 5). RIFIN and STEVOR hypervariable domains were originally believed to be
the only portions exposed on the erythrocyte surface, while the semiconserved do-
mains remained located within (16, 18). Recent work suggested a single transmem-
brane topology for some RIFINs and STEVORs, such that the semiconserved domain
would also be exposed on the host cell surface (18), which is consistent with our
ﬁndings. We previously showed that malaria-exposed sera react to the most conserved
sequences of P. falciparum erythrocyte membrane protein 1 (PfEMP1) (33), which,
coupled with these results, indicates that conserved sequences may be recognized by
the immune system before highly variable regions.
FIG 5 Peptides that were both serorecognized and differentially seroreactive in group comparisons were present in both RIFINs and STEVORs and captured
differences in ages and seasonal exposures. These peptides for adult-child comparisons were present in all (A) three RIFINs and (B) six STEVORs, including within
the second variable (V2) domain for RIFINs and in both the semiconserved (SC) and second variable (V2) domain for STEVORs. These peptides corresponding
to matched pediatric seasonal comparisons were sparse and not uniformly located within the three RIFINs (C), whereas the SC domain consistently harbored
such peptides in the STEVORs (D). The number of these peptides is listed to the right of each protein designation.
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The semiconserved domain has not previously been identiﬁed as a target of the
human immune response. A recent study used peptide microarrays to identify binding
sites of rabbit antibodies directed against RIFINs and STEVORs and localized this
reactivity to the C-terminal, intracellular conserved domain (34). A subsequent study
used a peptide array to identify regions of a RIFIN-A targeted by rosette-disrupting
pediatric sera (24). Surprisingly, antibodies bound not to the extracellular region but
instead to the conserved intracellular domain. In contrast to those studies, our current
study was the ﬁrst to compare malaria-exposed serologic responses of children to those
of adults, which allowed us to identify the semiconserved domain as a marker of
age-related malaria exposure.
We have previously shown that malaria-exposed sera react to the intracellular
portion of PfEMP1s (33). Although intracellular regions are likely shielded from antibody
recognition, these regions may become exposed to the immune system after erythro-
cyte lysis. Immune exposure after erythrocyte lysis may also explain the similar levels of
seroreactivity of different RIFIN types that we observed. The one RIFIN-A and two
RIFIN-Bs probed on both the protein and peptide microarrays did not have distinct
serorecognition and seroreactivity patterns in either age-related or seasonal compari-
sons. RIFIN-As are found on the surface of infected red blood cells and potentially
mediate erythrocyte adhesion (20). In contrast, RIFIN-Bs remain within the erythrocyte,
helping maintain parasite metabolism (6, 18). The ﬁnding of similar seroproﬁles of
RIFIN-As and RIFIN-Bs despite differences in functions and cellular location may have
been a consequence of immune exposure of both RIFIN types after erythrocyte lysis.
As such, these serologic responses may reﬂect malaria exposure but not protective
immunity.
Differences between the serologic responses of STEVORs and RIFINs may be linked
to differences in their respective functions, which are not fully understood. STEVORs
play a role in merozoite invasion and rosetting in vitro (25, 26). Our results revealed
peptides that were both serorecognized and differentially seroreactive in group com-
parisons localized within the semiconserved regions of six STEVORs. In a prior study,
peptides from these regions of a STEVOR bound native red blood cell surface proteins
(35). Sera raised against these STEVOR peptides inhibited in vitro invasion processes.
Antibodies to peptides that were both serorecognized and differentially seroreactive in
group comparisons that we have identiﬁed in the semiconserved regions of STEVORs
may protect against erythrocyte binding in clinical malaria syndromes and should be
evaluated further in in vitro studies.
It has previously been hypothesized that children acquire immunity to severe
malaria after a single malaria episode (11, 36). We showed a marked increase in
serorecognition to peptides of all of the STEVORs and RIFINs examined following a
clinical episode of malaria, including the three STEVORs and three RIFINs previously
associated with severe malaria vulnerability in Malian children (22). This rapid acquisi-
tion of antibodies to epitopes may indicate how severe malaria immunity could
develop after a single clinical episode. Interestingly, a study in Ghanaian children found
that antibodies to STEVOR PF3D7_0300400 did not protect naive Ghanaian children
from subsequent parasitemia; these antibodies served as a marker of infection but were
not associated with protective immunity (28). An immune response to a single STEVOR
may not confer protection against severe malaria, but a broad response to a larger set
of variant surface antigens may be a better predictor of protection against clinical
disease. Further microarray studies of a more comprehensive set of variant surface
antigens using sera from children with severe malaria may provide crucial insights into
speciﬁc targets of natural immunity.
This study had some limitations. Antigens on the protein microarray were fabricated
with a cell-free Escherichia coli-based transcription and translation system, which may
not represent the actual conformations of wild-type RIFINs or STEVORs. However, this
protein array platform has produced antibody responses to malaria vaccine candidate
antigens that closely correlate with measurements of puriﬁed versions of these proteins
using enzyme-linked immunosorbent assays (ELISAs) (37). Findings of studies per-
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formed with protein microarrays parallel predicted serological responses in malaria-
exposed children and adults (22, 33, 37, 38). Similarly, the short linear peptides used on
the peptide microarray may fail to capture conformational or discontinuous epitopes
that are important to antibody responses. Yet the majority of antibodies bind to short
amino acid sequences (39), and the 16-amino-acid peptides demonstrate some sec-
ondary structure, suggesting that conformational epitopes may still be present. While
we successfully detected signatures of exposure, some epitopes may have been missed
given the limited number of pediatric samples assayed. Finally, the RIFINs and STEVORs
included on the two microarrays comprise only a small subset of the many variants
found in the parasite. Our platforms may not include critical immunological variants of
these variant surface antigens.
Protein and peptide microarrays populated with a panel of RIFINs and STEVORs
associated with severe malaria vulnerability revealed that the semiconserved domains
of both RIFINs and STEVORs serve as markers of malaria exposure. To comprehensively
identify epitopes associated with severe malaria vulnerability and whether differences
in exposure are truly correlated with protection, protein and peptide microarrays
populated with a comprehensive set of RIFINs and STEVORs should be probed with sera
from severe malaria case-control studies. Further analyses and characterization of
relevant STEVORs and RIFINs through invasion inhibition, rosetting, and phagocytosis
assays will provide insight into the role each protein plays in the development of severe
malaria.
MATERIALS AND METHODS
Microarray construction and controls. Both the protein and peptide microarrays included three
full-length RIFIN antigens (PF3D7_0833200 [RIFIN-B], PF3D7_104110 [RIFIN-B], and PF3D7_0732400
[RIFIN-A]) and three full-length STEVOR antigens (PF3D7_0832000, PF3D7_0300400, and PF3D7_
0115400) associated with cerebral malaria vulnerability; PF3D7_0832000 is also associated with vulner-
ability to severe malarial anemia (22). We also included three additional 3D7 STEVORs (PF3D7_1300900,
PF3D7_0832600, and PF3D7_1254100) that were used to evaluate antibody responses in Ghanaian
children and adults (28). The signal peptide sequence was omitted from all proteins.
Protein microarray construction followed a four-step process: (i) PCR ampliﬁcation of each complete
or partial P. falciparum open reading frame, (ii) recombination cloning, (iii) in vitro transcription/
translation (IVTT), and (iv) microarray chip printing (29). This IVTT protein microarray platform has
produced antibody measurements that correlate with those of puriﬁed proteins of several malaria
vaccine candidate antigens on ELISAs (37). The peptide array represents protein sequences of interest
with a peptide tiling design incorporating peptides that are 16 amino acids in length, where the start
location of peptide sequences is offset by 4 amino acids (i.e., a 12-amino-acid sequence overlap between
contiguous peptides). After the design was ﬁnalized, peptide arrays were synthesized through light-
directed solid-phase peptide synthesis as previously described (30). Serum samples were bound to
peptide arrays and labeled with an anti-human IgG secondary antibody with an Alexa Fluor 647
ﬂuorescent label.
The amino acid positions of the start and ﬁnish of RIFIN and STEVOR domains for each antigen were
deﬁned using the PEXEL motif and transmembrane domains as anchors for bioinformatic alignment,
based on previous analyses and the PlasmoDB database (6, 7, 16, 20, 34, 40).
Study population. Arrays were probed with sera of individuals from Bandiagara, a town of 13,634
inhabitants (2002 census) in the Dogon region in east-central Mali. P. falciparum infections represent 97%
of the malaria infections in this region. Malaria transmission is sharply seasonal, with minimal transmis-
sion at the height of the dry season in March; fewer than one infected mosquito bite per person per
month at the start and end of the transmission season in June and December, respectively; and a peak
of up to 60 infected bites per person per month in September (41). Children experience one to two
clinical malaria episodes per season (42). The average age of a child with severe malaria is 38.7 months
(43), and the mean age of patients diagnosed with uncomplicated malaria is 10 years (44).
We probed protein microarrays with sera from Malian adults aged 18 to 55 years enrolled in the
control arm of a phase I AMA1 vaccine (FMP2.1/AS02A) trial (n 18) (48) and sera from Malian children
aged 1 to 6 years enrolled in the control arm of a phase II AMA1 vaccine (FMP2.1/AS02A) trial (n 75)
(45, 46). These serum samples were collected at the start of and during the malaria transmission season.
These control volunteers did not receive an intervention affecting their risk for malaria infection, allowing
study of natural immunity. Sera from 10 malaria-naive North American blood donors served as negative
controls.
A high-density peptide microarray was probed with sera from a subset of randomly selected
individuals whose sera was used for the protein microarray, including sera from 10 Malian adults and 10
Malian children and 5 malaria-naive North American control samples. Pediatric sera included time points
before (day 0) and during (day 90) the malaria transmission season. Among the 10 children, 6 subjects
experienced at least one clinical malaria episode before the day 90 time point, deﬁned as having malaria
symptoms and P. falciparum parasites on a blood smear. The average age for these six children at
Zhou et al.
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enrollment was 3.1 0.5 years (mean  standard error), compared to 4.3 0.2 years for the remaining
four children (P  0.06, Wilcoxon rank-sum test).
Ethics statement. The protocols were approved by institutional review boards of the University of
Bamako Faculty of Medicine; the University of Maryland, Baltimore; and the U.S. Army Surgeon General.
Written informed consent was obtained before screening and enrollment in the trials. Verbal consent of
illiterate parents or guardians was provided and documented using thumbprints and veriﬁed by
independent witnesses.
Statistical analysis. We applied data analysis techniques previously used to evaluate serologic
responses with P. falciparum protein microarrays (22, 37, 47). For protein microarrays, ﬂuorescence
intensity was deﬁned as the raw signal intensity value reduced by the mean for the no-DNA negative
controls to adjust for differences in seroreactivity to the IVTT reaction buffers and cell-free E. coli system.
Given the synthetic fabrication process for peptide microarrays, no adjustment for background ﬂuores-
cence intensity was necessary; raw ﬂuorescence intensity represented peptide seroreactivity. Group
serorecognition of a protein or peptide fragment was deﬁned as detection of a level of ﬂuorescence
intensity signiﬁcantly greater than that of the malaria-naive North American control group, based on a
two-sample Kolmogorov-Smirnov test. Serorecognition differences between two populations for the
peptide array were calculated with a two-tailed McNemar’s test. Levels of seroreactivity of a protein
fragment or peptide were compared among groups using a nonparametric Wilcoxon rank sum test for
unmatched group-wise comparisons. Levels of seroreactivity for paired samples across time points were
compared using a Wilcoxon signed-rank test. Finally, we identiﬁed peptides that not only were serorec-
ognized by a single population but also had differentially increased seroreactivity in a given comparison.
All P values presented represent two-sided values determined without correcting for multiple compar-
isons, as was previously done in other microarray analyses (22, 24, 38). Statistical analyses were computed
using either R Project for Statistical Computing (version 3.4.3) or GraphPad (version 5.04).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSphere.00097-19.
FIG S1, TIF ﬁle, 2.7 MB.
FIG S2, TIF ﬁle, 1.4 MB.
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